Bio-Techne 2026 Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Science Tools and Diagnostics Key Market Insights Pharma Market - Pharma represents approximately **30%** of Bio-Techne's revenue - Exited December quarter with **low double-digit growth**, marking the fifth consecutive quarter of double-digit growth [6][7] - Concerns regarding MFN pricing and tariffs were alleviated, leading to continued strong performance in large pharma [7][8] Biotech Market - Biotech accounts for about **20%** of revenue - Exited Q2 with **mid-single-digit declines** in biotech, which is seen as a positive outcome given a **40%** decline in biotech funding in the first half of 2025 [9][12] - Recent funding trends show signs of recovery, with funding increasing by **over 90%** exiting December [14][15] - M&A activity among large pharma acquiring biotechs is increasing, indicating a positive outlook for new investors [16] Academic Market - Academic market contributes a little over **20%** of global revenues, split evenly between Europe and the U.S. - European academic market shows **low- to mid-single-digit growth**, while U.S. academic market has stabilized with **low single-digit declines** [24][28] - Recent approval of a **1% increase** in NIH funding is a positive development, although the impact on spending is still uncertain [32][36] Asia Market - Asia accounts for **16%-17%** of revenue, with half from China - China has seen three consecutive quarters of growth, with double-digit growth in the rest of Asia [41][45] - Optimism is returning in China regarding government funding for biotechs, with increased licensing activity from pharma [62] Financial Guidance - For fiscal year 2026, Bio-Techne expects to exit Q4 with **mid-single-digit growth** [66] - Concerns about timing of recovery in funding translating into spending, with historical lag of **2-3 quarters** noted [79][81] - Anticipated headwinds from two large GMP customers, which have been significant contributors to revenue, are expected to lessen in Q4 [88][91] Growth Drivers - The cell therapy franchise has shown resilience, with **30% growth** among remaining customers excluding two large GMP customers [102] - Over **80 customers** are in clinical trials, indicating a robust pipeline [104] - The company expects a **floor of 20% growth** in a normal market for the remaining customer base [121] M&A Strategy - Bio-Techne remains committed to M&A as a priority for capital deployment, focusing on quality over quantity in potential acquisitions [141][156] - Areas of interest include cell therapy and organoids, with a belief that these sectors will continue to grow significantly [157] AI and Future Outlook - AI is viewed as a significant enhancement for the industry, with expectations that it will drive growth in life science tools over the next several years [175][180] - The company is actively using AI to develop next-generation proteins, which are expected to be a key growth area [175][189] Margin Expansion - Bio-Techne anticipates **100 basis points margin expansion** in 2026, driven by growth in differentiated products [196][199] - Historical growth rates suggest that mid-single-digit to high single-digit growth should yield at least **50 basis points** in margin expansion [199][203] Conclusion - Bio-Techne is positioned for growth across various markets, with positive trends in pharma, biotech, and academic sectors. The company is focused on strategic M&A, leveraging AI for innovation, and maintaining margin expansion through differentiated product offerings.

Group 1 - Gilead Sciences announced the acquisition of Arcellx, Inc. for up to $7.8 billion, paying $115 per share, which represents a 79% premium over Arcellx's last closing price [2] - Following the announcement, Arcellx's stock price surged by 77.9% to $114.06 in morning trading [2] - This acquisition is Gilead's largest since its $21 billion purchase of Immunomedics in 2020, as the company seeks to diversify beyond its traditional HIV and liver disease therapies [2][3] Group 2 - The acquisition enhances Gilead's position in cell therapy, particularly with an investigational CAR-T treatment for multiple myeloma, which is under FDA consideration as a fourth-line treatment [3] - Gilead expects the transaction to be finalized in the second quarter of 2026 [3] - Analysts suggest that the new treatment may have a better safety profile compared to existing therapies, indicating potential competitive advantages in the market [3]

Industry Overview - The biotech industry had a strong performance in 2025, outperforming NVIDIA, with continued enthusiasm into 2026 [5] - There are concerns regarding the FDA's regulatory environment, described as chaotic, which may impact drug approvals [5][9] FDA Regulatory Environment - Richard Pasdur, a former senior FDA executive, expressed concerns about the breach of the firewall between political appointees and drug reviewers, indicating potential risks for the pharma industry [7] - The FDA's current commissioner, Marty Makary, aims to speed up drug approvals, but there are conflicting signals regarding the actual operating reality [9] Company Earnings Predictions Eli Lilly (Ticker: LLY) - Expected earnings per share range from $6.99 to $7.86, with a consensus estimate of $7.48 and revenue of $17.85 billion, indicating over 30% year-over-year earnings growth [15] - Analysts predict a likely earnings beat due to a history of exceeding expectations [15][16] Novo Nordisk (Ticker: NVO) - Earnings per share expectations are between $0.89 and $0.90, with revenue projected at $11.96 billion, showing a flat to slightly down trend [17] - Analysts express a higher possibility of a miss compared to Eli Lilly, citing recent struggles and a new CEO's uncertain direction [17][19] Twist Bioscience (Ticker: TWST) - Reported revenue of $104 million for Q1 2026, consistent with preliminary results, though still unprofitable [20] - The company has shown consistent revenue growth despite industry challenges, reducing cash burn and moving towards profitability [20]

Summary of Artiva Biotherapeutics Conference Call Company Overview - **Company**: Artiva Biotherapeutics (NasdaqGM:ARTV) - **Lead Product**: AlloNK, a non-genetically modified NK cell therapy targeting autoimmune diseases - **Financial Position**: As of Q3, the company reported $123 million in cash, providing a runway into Q2 2027 [1][2] Industry Context - **Targeted Therapies**: The company aims to position AlloNK within the deep B-cell depletion space, similar to existing therapies like TNF inhibitors and JAK inhibitors, which are significant in treating autoimmune diseases [3] - **Market Opportunity**: The refractory rheumatoid arthritis (RA) market is highlighted as a key focus, with over 150,000 patients in the U.S. alone, indicating a substantial unmet need for effective treatments [31][36] Core Points and Arguments - **Clinical Development**: Over 100 patients have been dosed with AlloNK across oncology and autoimmune diseases, with initial safety data from 32 patients treated in autoimmune studies showing no significant toxicities [1][15] - **Mechanism of Action**: AlloNK utilizes monoclonal antibodies to target B-cells, leveraging ADCC via the CD16 receptor, which is expected to provide higher efficacy with favorable safety compared to traditional biologics [5][6] - **Treatment Regimen**: The regimen involves low doses of cyclophosphamide and fludarabine as conditioning agents, followed by AlloNK and rituximab, designed for outpatient administration [10][11] - **Safety Profile**: Initial safety data indicates no severe treatment-emergent adverse events, with a low rate of infections and no cases of cytokine release syndrome (CRS) or neurotoxicity [16][17] Key Data Points - **Efficacy in Oncology**: In a study of 14 patients with aggressive non-Hodgkin lymphoma, a 64% complete response rate was achieved, with a minimum duration of response of 19.4 months [7] - **B-cell Depletion**: AlloNK plus anti-CD20 monoclonal antibody demonstrated complete B-cell depletion in all patients by day 13, with reconstitution observed around six months [24][25] - **Durability of Response**: The company aims for a median duration of response of 12-24 months, with the potential for patients to be weaned off immunomodulatory drugs post-treatment [12][45] Additional Insights - **Regulatory Strategy**: Artiva plans to engage with the FDA regarding pivotal trial design for refractory RA in the first half of 2026, with a focus on demonstrating significant clinical responses [38][58] - **Market Landscape**: The company identifies a gap in late-stage development for therapies targeting refractory RA, positioning AlloNK as a potential first deep B-cell depleting agent in this space [37][58] - **Patient Demographics**: The treatment has been well-tolerated in older patients, with no specific concerns raised regarding safety in this demographic [51][52] Conclusion Artiva Biotherapeutics is advancing its AlloNK therapy with promising initial safety and efficacy data in autoimmune diseases, particularly in refractory RA. The company is strategically positioned to address significant unmet needs in the market, with plans for further clinical development and regulatory engagement in the near future.

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 240 patents [1][5] - The company presented research on a scalable artificial thymus organoid at the ThymUS 2025 Meeting, which aims to recover the functionality of the thymus [2][3] Company Overview - Founded in 2001, FibroBiologics is based in Houston and is engaged in developing a pipeline of treatments for various chronic diseases, including multiple sclerosis, cancer, and wound healing [5] - The company emphasizes the unique immunomodulatory properties of fibroblasts, which are believed to enhance the functionality and durability of therapeutic organoids [3][5] Research and Development - The presented abstract details a method for developing transplantable and scalable thymus organoids that can generate functional T cells, indicating significant progress in the field [2][3] - The research highlights the potential of organoids to transform the study and treatment of chronic diseases, showcasing the innovative approaches being explored by the company [3]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $57 million, aligning with expectations, and full year revenues of $259 million, near the midpoint of the previously stated range of $255 million to $265 million [10] - GAAP net loss before non-controlling interests was $46 million for Q4 2024, compared to a loss of $110 million in Q4 2023, while the annual net loss was $260 million, up from $138 million in 2023 [12] - Adjusted EBITDA for Q4 2024 was a negative $1 million, down from $21 million in Q4 2023, with a full year adjusted EBITDA of $36 million, reflecting a margin of 14% [12][13] Business Line Data and Key Metrics Changes - The Biologic Safety Testing segment generated $15 million in Q4 and $63 million for the full year, with an adjusted EBITDA margin of approximately 70% [10][17] - The Nucleic Acid Production segment reported revenues of $42 million in Q4, including $14 million from high volume clean cap sales, and $196 million for the full year, with an adjusted EBITDA margin of 26% [10][17] Market Data and Key Metrics Changes - Revenue breakdown by customer type for 2024 showed 48% from biopharma, 25% from life sciences and diagnostics, 5% from CROs, CMOs, and CDMOs, 4% from academia, and 18% through distributors [11] - The company’s exposure to China was $13.6 million for the full year, with expectations for flat growth in 2025 [69] Company Strategy and Development Direction - The company is focused on returning its base business to growth, anticipating revenues of $185 million to $205 million for 2025, excluding high volume clean cap [19][20] - Strategic investments include expanding commercial footprint, enhancing intellectual property protection, and integrating recent acquisitions to drive growth in the discovery area [30][63] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in forecasting due to market dynamics but expressed confidence in the company’s capabilities and growth opportunities [19][24] - The company is enhancing visibility into customer clinical programs to better predict sales and manage operations [27][35] Other Important Information - The company ended 2024 with $322 million in cash and $300 million in long-term debt, resulting in a net cash position of $22 million [14] - Capital expenditures for 2024 were $30 million, with expectations for a decline to $15 million to $20 million in 2025 [23][15] Q&A Session Summary Question: Can you provide guidance on gross margins for 2025? - Management indicated that the cost structure for 2025 will remain consistent with 2024, with fixed costs around $200 million and variable costs expected to range between 10% to 12% [46][47] Question: How is the company improving visibility with key customers? - Management noted that new agreements include mandatory disclosure requirements for clinical trial milestones, which should enhance visibility into customer programs [52][53] Question: What are the expectations for segment growth and revenue cadence? - Management expects Q1 2025 revenues to be between $43 million to $45 million, with growth anticipated in the back half of the year driven by acquisitions and new product introductions [56][58] Question: What are the capital allocation priorities for 2025? - The company plans to focus on reducing cash interest expenses and is open to evaluating M&A opportunities that align with their strategic goals [62][63] Question: How much of the revenue forecast is related to COVID vaccine contributions? - Management stated that the forecast excludes any contributions from COVID-related revenues, reflecting a shift in focus to base business growth [80][82] Question: What percentage of revenue did the top 10 customers comprise for 2024? - The top 10 customers accounted for 46% of revenue in 2024, showing a gradual diversification from 48% in 2023 [84]